Ancora Pharma said that each eligible project was awarded approximately $244,000 through the program.
The National Institutes of Health grants were awarded to projects with potential to result in new therapies to treat areas of unmet medical need, prevent chronic or acute diseases or reduce the long-term growth of health care costs in the US.
Ancora Pharma president John Pena said that they have the opportunity to make a tremendous global impact on the preventative standard of care for millions of individuals with our vaccine candidates.
"These grants will help us continue development of these products," Pena said.